Since inflammation is known to play a role in the left ventricular hypertrophy of CKD patients [52, 53], one may speculate that an anti‐inflammatory effect of apoA‐IV could counteract this effect of inflammation. The gene discussed is APOA4; the disease is left ventricular hypertrophy.